VCANBIO(600645)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was CNY 404,288,544.80, a decrease of 0.77% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 49,836,990.44, reflecting a slight increase of 0.24% year-on-year[5]. - The net profit excluding non-recurring gains and losses reached CNY 46,420,855.62, up by 5.25% compared to the previous year[5]. - Year-to-date net profit attributable to shareholders increased by 15.68% to CNY 132,511,715.75[5]. - Total operating revenue for the first three quarters of 2023 reached ¥1,202,361,554.62, a slight increase from ¥1,176,215,892.32 in the same period of 2022, representing a growth of approximately 2.1%[19]. - Net profit for the first three quarters of 2023 was ¥129,363,556.18, up from ¥113,460,668.07 in 2022, reflecting an increase of approximately 14.0%[21]. - Earnings per share for the third quarter of 2023 were ¥0.28, compared to ¥0.24 in the same quarter of 2022, marking a growth of 16.7%[21]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,422,684,073.67, representing a growth of 2.61% from the end of the previous year[6]. - As of September 30, 2023, the company's total assets amounted to RMB 5,422,684,073.67, an increase from RMB 5,284,619,414.55 in December 2022, reflecting a growth of approximately 2.62%[14]. - The total liabilities as of the end of the third quarter of 2023 amounted to ¥1,607,328,973.59, a slight decrease from ¥1,630,964,993.11 at the end of 2022[20]. - The total current liabilities were RMB 1,458,579,250.56, slightly decreased from RMB 1,471,494,581.46 in December 2022, showing a reduction of about 0.88%[15]. - The total equity attributable to shareholders of the parent company increased to ¥3,699,101,217.49 from ¥3,555,802,379.28, representing a growth of approximately 4.0%[20]. Cash Flow - The company reported a cash flow from operating activities of CNY 185,611,359.85, an increase of 4.10% year-to-date[5]. - Cash flow from operating activities for the first three quarters of 2023 was ¥1,237,616,152.41, compared to ¥1,201,322,207.24 in 2022, indicating an increase of about 3.0%[23]. - The net cash inflow from operating activities for Q3 2023 was 178,308,231.45 in Q3 2022, representing a growth of approximately 1.8%[24]. - The total cash and cash equivalents at the end of Q3 2023 amounted to 1,317,810,007.20 in Q3 2022, reflecting an increase of approximately 14.5%[25]. Investments and Expenses - Total cash inflow from investment activities was 3,025,864.67 in the same period last year, indicating a significant increase[24]. - The net cash outflow from investment activities was -71,251,901.56 in Q3 2022[24]. - Research and development expenses for the first three quarters of 2023 were ¥117,503,490.16, up from ¥109,497,085.50 in 2022, reflecting an increase of approximately 7.3%[20]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 37,602[10]. - The company's goodwill remained stable at RMB 702,913,535.62, unchanged from December 2022[15]. Other Information - The company has not provided specific guidance for future performance or new product developments in the current report[13]. - The company reported a decrease in other comprehensive income for the third quarter of 2023, with a net amount of ¥14,540,513.38 compared to a loss of ¥31,990,174.02 in the same period of 2022[21]. - The impact of exchange rate changes on cash and cash equivalents was 42,921,457.97 in the previous year[25].